JAKAVI® (ruxolitinib) myelofibrosis overview | HCP

Home > About myelofibrosis

Is it time to reconsider initial treatment choice for your myelofibrosis patients?

A serious disease requires rapid action

Approximately half of myelofibrosis patients die within 2-4 years and symptoms can be devastating^[1]
Watchful waiting can be detrimental to survival, even in intermediate-risk patients^[1]
Only JAKAVI offers significant spleen reduction, superior symptom control, and up to a 65% reduction in risk of death at 5 years compared with best available therapy (BAT)^[2]^,^[3]*

Results from an exploratory analysis of pooled data from 528 patients in the COMFORT-I and COMFORT-II trials. Seventy percent of patients in the control group crossed over to JAKAVI during the study. The control group in COMFORT-I received placebo. The control group in COMFORT-II received BAT; the three most common were hydroxyurea (47%), no medication (33%), and prednisone/prednisolone (12%). The crossover-corrected treatment effect was estimated using a rank-preserving structural failure time (RPSFT) method and through censorship of survival time at time of crossover.

How do survival outcomes in MF compare with other more timely treated malignancies?^[4]^,^[5]

5-year survival rates in select cancers

Early treatment with the maximum tolerated dose of JAKAVI offers your MF patients their best chance at extended survival^[6]

Myelofibrosis is aggressive, yet historically has been treated conservatively

Overall survival (OS) is poor, regardless of risk group^[1]

myelofibrosis survival rate beyond 4 years chart

Approximately half of patients with myelofibrosis survive beyond 4 years and even lower-risk patients have significantly reduced survival^[1]

Survival rates of low-risk myelofibrosis patients compared to the general population

survival rates of low-risk myelofibrosis patients chart

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CLL; chronic lymphocytic
leukaemia; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; SEER, Surveillance,
Epidemiology, and End Results.
*In a real-world analysis of 428 MF patients from academic centers in Italy and the Mayo Clinic, the 5-year survival rate was approximately 60.0%.
^†The overall median survival is based on an analysis of 1054 patients with primary MF from seven institutions in both the US and Europe, while the 5-year survival rate presented in the graph is based on an analysis of 20,250 patients with MPNs from the US National Cancer Institute SEER registries database.

See the superior survival results with JAKAVI

Learn about dosing and adjustments

See the safety data from the JAKAVI clinical trials

References

Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
National Cancer Institute. SEER cancer stat fact sheets. http://seer.cancer.gov/statfacts/. Accessed June 22, 2021.
Brunner AM, Hobbs G, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymph. 2016;57(5):1197-1200.
Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.